These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 29274619)

  • 1. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
    Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
    Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
    Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.
    Lee CL; O'Kane GM; Mason WP; Zhang WJ; Spiliopoulou P; Hansen AR; Grant RC; Knox JJ; Stockley TL; Zadeh G; Chen EX
    Mol Cancer Ther; 2024 Mar; 23(3):394-399. PubMed ID: 38015561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
    Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
    Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
    Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
    Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
    Rakheja D; Fuda F; Vandergriff T; Boriack R; Medeiros BC; Frankel AE; Chen W
    Hum Pathol; 2015 Feb; 46(2):322-6. PubMed ID: 25481493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
    DiNardo CD; Propert KJ; Loren AW; Paietta E; Sun Z; Levine RL; Straley KS; Yen K; Patel JP; Agresta S; Abdel-Wahab O; Perl AE; Litzow MR; Rowe JM; Lazarus HM; Fernandez HF; Margolis DJ; Tallman MS; Luger SM; Carroll M
    Blood; 2013 Jun; 121(24):4917-24. PubMed ID: 23641016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
    Grassian AR; Pagliarini R; Chiang DY
    Curr Opin Gastroenterol; 2014 May; 30(3):295-302. PubMed ID: 24569570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
    Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY
    J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.
    Yuan BF
    Adv Exp Med Biol; 2021; 1280():161-172. PubMed ID: 33791981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
    Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
    Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
    Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
    Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma.
    Churchill H; Naina H; Boriack R; Rakheja D; Chen W
    Int J Clin Exp Pathol; 2015; 8(9):11753-9. PubMed ID: 26617922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
    Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Goparaju R; Schwarzer A; Görlich K; Schottmann R; Struys EA; Jansen EE; Rohde C; Müller-Tidow C; Geffers R; Göhring G; Ganser A; Thol F; Heuser M
    Leukemia; 2016 Aug; 30(8):1708-15. PubMed ID: 27063596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
    Capper D; Simon M; Langhans CD; Okun JG; Tonn JC; Weller M; von Deimling A; Hartmann C;
    Int J Cancer; 2012 Aug; 131(3):766-8. PubMed ID: 21913188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.